Our Experience Of The Non-Diffractive Extended Depth-Of-Focus Iol Implantation For Presbyopia Correction
Published 2023 - 41st Congress of the ESCRS
Reference: PP05.07 | DOI: 10.82333/8q2t-jy18
Authors: Maria Konovalova* 1 , Mikhail Konovalov 1 , Kirill Pershin 2 , Nadezda Pashinova 2 , Konstantin Burdel 1 , Alexandr Tsygankov 2
1Konovalov Eye Center,Moscow,Russian Federation, 2Eximer Eye Center,Moscow,Russian Federation
The aim of our study was to evaluate visual performance, patient’s satisfaction, the incidence of adverse optical phenomena and the degree of patient satisfaction after the AcrySof IQ Vivity® IOL implantation up to 6 months after the surgery and contribute a comparative analysis with the results shown after the implantation of AcrySof IQ PanOptix® IOL.
The research was carried out in two ophthalmology clinics: Konovalov Eye Center and Eximer Eye Center.
This retrospective non-randomized trial inclided 84 patients (128 eyes) with presbyopia, who underwent phacoemulsification or refractive lensectomy with the AcrySof IQ Vivity® extended depth-of-focus IOL (n=20 eyes) and AcrySof IQ PanOptix® multifocal IOL implantation (n=108 eyes). Mean age of the pateints was 61.2±11.8 years. Detailed ophthalmic evaluation was carried out including distance, intermediate and near corrected and uncorrected visual acuities at 4 meters, 60 and 40 centimeters, contrast sensitivity, obejctive halometry and patient's satisfaction using VF-14 questionnaire. IOL power calculation was done using Barrett Universal II formula.
In the period of 6 months after the surgery UCVA and BCVA in both groups was comparably high (AcrySof IQ Vivity® UCVA 0.95±0.29; BCVA 1.06±0.1; AcrySof IQ PanOptix®-UCVA 0.93±0.18, BCVA 1.0±0.04). UCVA for near in the study group 0.41±0.16; in the comparison group 0.85±0.22. UCVA for intermediate distance 0.52±0.17; in the comparison group 0.84±0.24. Mean result of life quality VF-14 questionnaire was:83.0±6.5 points in the study group and 97.9±1.2 points in the PanOptix® group. One patient after the implantation of Vivity® IOL complained of glare, in the comparison group 24% of patients complained of various optical phenomena. Contrast sensitivity was higher in the Vivity® group at all frequencies in both photopic and mesopic conditions.
Satisfactory visual outcome was achieved following the implantation of AcrySof IQ Vivity® IOL. Patients that require high visual aquity in far distance especially in low light conditions without adverse optical phanomena and are tolerable to the use of reading glasses would make better candidates for AcrySof IQ Vivity® IOL impolantation than for AcrySof IQ PanOptix® IOL.